Effect of <font color="blue">rosuvastatin_4</font> <font color="blue">monotherapy_4</font> <font color="blue">or_3</font> <font color="blue">in_3</font> <font color="blue">combination_3</font> <font color="blue">with_3</font> <font color="blue">fenofibrate_4</font> <font color="blue">or_4</font> <font color="blue">ω-3_4</font> <font color="blue">fatty_4</font> <font color="blue">acids_4</font> <font color="blue">on_1</font> <font color="blue">lipoprotein_2</font> <font color="blue">subfraction_1</font> <font color="blue">profile_1</font> in patients with mixed <font color="blue">dyslipidaemia_1</font> <font color="blue">and_1</font> <font color="blue">metabolic_1</font> <font color="blue">syndrome_1</font> <font color="blue">._1</font> 
<br>
<br> BACKGROUND Raised <font color="blue">triglycerides_1</font> <font color="blue">(_1</font> <font color="blue">TG_1</font> <font color="blue">)_1</font> <font color="blue">,_1</font> decreased <font color="blue">high_1</font> <font color="blue">-_1</font> <font color="blue">density_1</font> <font color="blue">lipoprotein_1</font> <font color="blue">cholesterol_1</font> <font color="blue">(_1</font> <font color="blue">HDL_1</font> <font color="blue">-_1</font> <font color="blue">C_1</font> <font color="blue">)_1</font> levels and a predominance of <font color="blue">small_1</font> <font color="blue">dense_1</font> <font color="blue">low_1</font> <font color="blue">density_1</font> <font color="blue">lipoproteins_1</font> <font color="blue">(_1</font> <font color="blue">sdLDL_1</font> <font color="blue">)_1</font> are characteristics of the <font color="blue">metabolic_1</font> <font color="blue">syndrome_1</font> ( MetS ) . 
<br> OBJECTIVE To compare the effect of <font color="blue">high_2</font> <font color="blue">-_2</font> <font color="blue">dose_2</font> <font color="blue">rosuvastatin_5</font> <font color="blue">monotherapy_4</font> <font color="blue">with_1</font> <font color="blue">moderate_2</font> <font color="blue">dosing_2</font> <font color="blue">combined_2</font> <font color="blue">with_2</font> <font color="blue">fenofibrate_5</font> <font color="blue">or_3</font> <font color="blue">ω-3_4</font> <font color="blue">fatty_4</font> <font color="blue">acids_4</font> <font color="blue">on_3</font> <font color="blue">the_3</font> <font color="blue">lipoprotein_3</font> <font color="blue">subfraction_2</font> <font color="blue">profile_1</font> in patients with mixed <font color="blue">dyslipidaemia_1</font> and MetS. 
<br> METHODS We previously randomised patients with <font color="blue">low_2</font> <font color="blue">-_2</font> <font color="blue">density_2</font> <font color="blue">lipoprotein_2</font> <font color="blue">cholesterol_2</font> <font color="blue">(_1</font> <font color="blue">LDL_1</font> <font color="blue">-_1</font> <font color="blue">C_1</font> <font color="blue">)_1</font> <font color="blue">>_1</font> <font color="blue">160_1</font> <font color="blue">and_1</font> <font color="blue">TG_1</font> <font color="blue">>_1</font> <font color="blue">200_1</font> <font color="blue"> _1</font> <font color="blue">mg_1</font> <font color="blue">/_1</font> <font color="blue">dl_1</font> to <font color="blue">rosuvastatin_5</font> <font color="blue">monotherapy_4</font> <font color="blue">40_2</font> <font color="blue"> _2</font> <font color="blue">mg_2</font> <font color="blue">/_2</font> <font color="blue">day_2</font> <font color="blue">(_1</font> <font color="blue">R_2</font> <font color="blue">group_2</font> <font color="blue">,_2</font> <font color="blue">n_1</font> <font color="blue">=_1</font> <font color="blue">30_1</font> <font color="blue">)_1</font> <font color="blue">or_1</font> <font color="blue">rosuvastatin_5</font> <font color="blue">10_3</font> <font color="blue">mg_3</font> <font color="blue">/_3</font> <font color="blue">day_3</font> <font color="blue">combined_2</font> <font color="blue">with_2</font> <font color="blue">fenofibrate_5</font> <font color="blue">200_2</font> <font color="blue">mg_2</font> <font color="blue">/_2</font> <font color="blue">day_2</font> <font color="blue">(_2</font> <font color="blue">RF_2</font> <font color="blue">group_2</font> <font color="blue">,_2</font> <font color="blue">n_1</font> <font color="blue">=_1</font> <font color="blue">30_1</font> <font color="blue">)_1</font> <font color="blue">or_2</font> <font color="blue">ω-3_3</font> <font color="blue">fatty_3</font> <font color="blue">acids_3</font> <font color="blue">2_1</font> <font color="blue">g_1</font> <font color="blue">/_1</font> <font color="blue">day_1</font> <font color="blue">(_1</font> <font color="blue">Rω_2</font> <font color="blue">group_2</font> <font color="blue">,_2</font> <font color="blue">n_1</font> <font color="blue">=_1</font> <font color="blue">30_1</font> <font color="blue">)_1</font> <font color="blue">._1</font> In the present study , only patients with MetS were included <font color="blue">(_1</font> <font color="blue">24_1</font> <font color="blue">,_1</font> <font color="blue">23_1</font> <font color="blue">and_1</font> <font color="blue">24_1</font> <font color="blue">in_1</font> <font color="blue">the_1</font> <font color="blue">R_1</font> <font color="blue">,_1</font> <font color="blue">RF_1</font> <font color="blue">and_1</font> <font color="blue">Rω_1</font> <font color="blue">groups_1</font> <font color="blue">respectively_1</font> <font color="blue">)_1</font> <font color="blue">._1</font> At baseline and after 12 weeks of treatment , the <font color="blue">lipoprotein_1</font> <font color="blue">subfraction_1</font> profile was determined by <font color="blue">polyacrylamide_1</font> <font color="blue">3%_1</font> <font color="blue">gel_1</font> <font color="blue">electrophoresis_1</font> <font color="blue">._1</font> 
<br> RESULTS The mean <font color="blue">LDL_1</font> size was significantly increased in all groups . This change was more prominent with <font color="blue">RF_2</font> than with other treatments in parallel with its greater hypotriglyceridemic capacity ( p < 0.05 compared with R and Rω ) . A decrease in insulin resistance by <font color="blue">RF_1</font> was also noted . Only <font color="blue">RF_2</font> significantly raised <font color="blue">HDL_1</font> <font color="blue">-_1</font> <font color="blue">C_1</font> <font color="blue">levels_1</font> <font color="blue">(_1</font> <font color="blue">by_1</font> <font color="blue">7.7%_1</font> <font color="blue">,_1</font> <font color="blue">p_1</font> <font color="blue"><_1</font> <font color="blue">0.05_1</font> <font color="blue">)_1</font> by increasing the cholesterol of small <font color="blue">HDL_1</font> particles . The <font color="blue">cholesterol_1</font> of larger <font color="blue">HDL_1</font> subclasses was significantly increased by <font color="blue">R_2</font> <font color="blue">and_1</font> <font color="blue">Rω._2</font> 
<br> CONCLUSIONS All <font color="blue">regimens_1</font> increased mean <font color="blue">LDL_1</font> size ; <font color="blue">RF_1</font> was the most effective . A differential effect of treatments was noted on the <font color="blue">HDL_1</font> subfraction profile .